Riyaz Sumar, MD
Cardiovascular Disease · Avondale, AZNPI 1144212721
Payments from drug & device makers
Across 299 payments — averaging $258.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$30K
- Bayer$18K
- Terumo Medical Corporation$14K
- Angiodynamics, Inc.$7K
- Abbott$3K
- Abiomed$2K
- plus $3K from 24 others
Across 1 payment — averaging $145.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$146
What the payments were for
- Consulting fees$2,5008%
- Speaking & faculty fees$10,80036%
- Travel & lodging$1,6826%
- Food & beverage$8,47028%
- Education$460%
- Other$6,56722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 20 | $30,250 |
| Bayer | 6 | $18,246 |
| Terumo Medical Corporation | 20 | $13,702 |
| Angiodynamics, Inc. | 11 | $6,759 |
| Abbott | 97 | $2,534 |
| Abiomed | 37 | $2,399 |
| Shockwave Medical, Inc | 11 | $999 |
| Saranas, Inc. | 21 | $711 |
| Medtronic(2 entities) | 13 | $286 |
| Novartis | 12 | $270 |
| Philips North America LLC | 7 | $196 |
| Organogenesis Inc. | 1 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $125 |
| Surmodics, Inc. | 4 | $106 |
| Boston Scientific | 4 | $100 |
| Bard Peripheral Vascular, Inc. | 4 | $72 |
| Penumbra, Inc. | 2 | $70 |
| Amgen | 3 | $60 |
| Johnson & Johnson | 1 | $46 |
| Merck | 3 | $37 |
| Cook Medical LLC | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Pfizer | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Bardy Diagnostics, Inc. | 1 | $25 |
| Cordis US CORP. | 1 | $25 |
| Endologix LLC | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Biotronik Inc. | 1 | $21 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLIDESHEATH SLENDER$10,800
- Auryon Laser System 100-120 Vac$6,567
- Glidesheath$2,626
- Impella$1,786
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$767
- Coronary Orbital Atherectomy System$729
- AVEIR$250
- Peripheral Orbital Atherectomy System$180
- PuraPly$148
- Merlin Connectivity and Remote$138
- Navicross$126
- GlideWire$126
- Quadra Assura CRT Defibrillator$125
- Diamondback Peripheral$120
- Diamondback Coronary$120
- Perclose ProGlide suture mediated closure system$116
How this compares
$77,352 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $103,770 |
| XareltoRivaroxaban | 80 | $100,392 |
| BrilintaTicagrelor | 32 | $29,366 |
| Repatha SureclickEvolocumab | 20 | $21,904 |
| EntrestoSacubitril/Valsartan | 22 | $16,795 |
| NorvascAmlodipine Besylate | 13 | $4,212 |
| ClopidogrelClopidogrel Bisulfate | 297 | $3,185 |
| Atorvastatin Calcium | 194 | $2,050 |
| Metoprolol Succinate | 131 | $1,771 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 40 | $1,528 |
| Carvedilol | 111 | $1,132 |
| Digoxin | 31 | $1,064 |
| Rosuvastatin Calcium | 53 | $922 |
| Potassium Chloride | 35 | $767 |
| Hydralazine Hcl | 28 | $622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $103,77099 claims |
| Johnson & JohnsonXarelto | $46 | $100,39280 claims |
| AstraZenecaBrilinta | $12 | $29,36632 claims |
| NovartisEntresto | $270 | $16,79522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Avondale
- David RizikScottsdale$2.1M
- Rodrigo ChanMesa$2M
- Ashish GuptaPhoenix$1.2M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Gregory KoshkarianTucson$608K
- Andrew KaplanMesa$455K
- Charles JostMesa$374K
- Steven MottlTucson$340K
- Steven LesterScottsdale$336K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.